Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

View slated interviews with experts as well as insights from urologists on what to watch for. 

Conference Preview: American Urological Association 2025 

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD. 

Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

Hugec is a medical oncologist and hematologist at Minnesota Oncology in Maplewood.

"We’ve achieved a lot, but the focus now must shift from cure alone to comprehensive, patient-centered care," says Vladimir Hugec, MD.

Testicular Cancer Awareness Month: Advances and controversies in testicular cancer care 

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025. 

10 urology trials in progress to be highlighted at AUA 2025

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Exploring Treatments for Metastatic Castration-Sensitive Prostate Cancer

Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy  

Video content above is prompted by the following:

What are the guideline-recommended treatment options for patients with mCSPC (“castration-naive” CSPC)?

Videos

Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.

Emerging Trends and Rising Prevalence of  mCSPC

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.

Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.

Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.

Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

Panelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.

Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.

Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.

Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy 

Management of metastatic castration-sensitive prostate cancer (mCSPC) involves a combination of androgen deprivation therapy (ADT) and additional systemic therapies. Guideline-recommended treatment options include the use of ADT in conjunction with agents such as docetaxel, abiraterone acetate, enzalutamide, or apalutamide. These therapies have been shown to improve overall survival and progression-free survival in patients with mCSPC. The choice of treatment is influenced by factors such as patient comorbidities, disease burden, and patient preference, emphasizing the need for individualized treatment plans.

Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

Key Takeaways

EP: 1.Emerging Trends and Rising Prevalence of mCSPC

EP: 2.Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP: 3.Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP: 4.Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP: 5.Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP: 6.Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP: 7.Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy